- Trials with a EudraCT protocol (11,641)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11,641 result(s) found for: 30 - 15.
Displaying page 522 of 583.
EudraCT Number: 2014-004519-35 | Sponsor Protocol Number: PANC2002 | Start Date*: 2015-01-09 |
Sponsor Name:Abbott Laboratories GmbH | ||
Full Title: A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects with Pancreat... | ||
Medical condition: Pancreatic exocrine Insufficiency due to Cystic Fibrosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-002328-14 | Sponsor Protocol Number: OC3-DB-01 | Start Date*: 2008-01-10 | |||||||||||
Sponsor Name:OxThera Inc. | |||||||||||||
Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary H... | |||||||||||||
Medical condition: primary hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003459-64 | Sponsor Protocol Number: AFX01_202 | Start Date*: 2009-03-18 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
Full Title: A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and... | |||||||||||||
Medical condition: Anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019690-15 | Sponsor Protocol Number: GLP114179 | Start Date*: 2010-07-27 | |||||||||||
Sponsor Name:GlaxoSmithKline LLC | |||||||||||||
Full Title: Estudio multicéntrico, aleatorizado, abierto y de grupos paralelos para determinar la eficacia y la seguridad de albiglutida en comparación con liraglutida en pacientes con diabetes mellitus de tip... | |||||||||||||
Medical condition: Diabetes mellitus de tipo 2. Type 2 Diabetes Mellitus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004222-17 | Sponsor Protocol Number: H6D-MC-LVHX | Start Date*: 2009-01-30 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, PLacebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhib... | |||||||||||||
Medical condition: Erectile dysfunction. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023483-41 | Sponsor Protocol Number: I10E-0718 | Start Date*: 2011-03-01 | |||||||||||||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||||||||||||
Full Title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID) | |||||||||||||||||||||||
Medical condition: a primary immunodeficiency as defined by the ESID and validated by a reference centre : • X-linked agammaglobulinemia (XLA) • Common variable immunodeficiency (CVID) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) FR (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2013-003452-21 | Sponsor Protocol Number: BRF117277 | Start Date*: 2014-01-27 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. | |||||||||||||
Medical condition: Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003669-14 | Sponsor Protocol Number: ISRCTN15088122 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:London School Of Hygiene and Tropical Medicine | |||||||||||||
Full Title: Tranexamic Acid for the treatment of significant traumatic brain injury: an international, randomised, double blind, placebo controlled trial. | |||||||||||||
Medical condition: Traumatic Brain Injury | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) IT (Completed) IE (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005523-42 | Sponsor Protocol Number: 905-EC-005 | Start Date*: 2007-09-05 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride ... | |||||||||||||
Medical condition: Neurogenic detrusor overactivity. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) NL (Completed) GB (Completed) HU (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002576-18 | Sponsor Protocol Number: A4061027 | Start Date*: 2006-11-24 | |||||||||||
Sponsor Name:Pfizer Ltd. | |||||||||||||
Full Title: A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT | |||||||||||||
Medical condition: Treatment of patients with 131I-refractory metastatic or unresectable locally-advanced papillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of, or have cl... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002694-52 | Sponsor Protocol Number: 1012.56 | Start Date*: 2007-01-05 | |||||||||||
Sponsor Name:Boehringer Ingelheim France | |||||||||||||
Full Title: A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety... | |||||||||||||
Medical condition: Adults with Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006375-21 | Sponsor Protocol Number: F3Z-MC-IOOZ(a) | Start Date*: 2007-04-12 | |||||||||||
Sponsor Name:Eli Lilly and Company Ltd. | |||||||||||||
Full Title: The COMPLETE T1D Trial: COMParison of Insulin Lispro Protamine Suspension and DETEmir in Type 1 Diabetes Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Det... | |||||||||||||
Medical condition: type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000362-38 | Sponsor Protocol Number: BBW-11 | Start Date*: 2012-06-18 | |||||||||||
Sponsor Name:Birken AG | |||||||||||||
Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in... | |||||||||||||
Medical condition: Superficial partial-thickness (grade 2a) burn wounds | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000627-13 | Sponsor Protocol Number: C201 | Start Date*: 2018-06-06 | ||||||||||||||||||||||||||
Sponsor Name:GAMAMABS Pharma | ||||||||||||||||||||||||||||
Full Title: OPEN, NON CONTROLLED, PARALLEL COHORTS, MULTICENTER, PHASE 2A STUDY FOR THE EVALUATION OF THE ANTITUMOR ACTIVITY OF GM102 SINGLE AGENT AND IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ... | ||||||||||||||||||||||||||||
Medical condition: Patients with locally advanced or metastatic colorectal cancer (CRC), having received at least two lines of therapy for the locally advanced or metastatic CRC disease. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: CZ (Completed) BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005264-86 | Sponsor Protocol Number: 1182.98 | Start Date*: 2007-02-21 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p... | ||
Medical condition: The objective of this study is to demonstrate the safety and efficacy of TPV/r among a racially diverse HIV-positive population of females and males who are three-class (NRTI, NNRTI, and PI) experi... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-004338-26 | Sponsor Protocol Number: FE200486 CS28 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: Ensayo clínico abierto, aleatorizado, de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción de la puntuación en la es... | |||||||||||||
Medical condition: Cáncer de próstata | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) GB (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001578-17 | Sponsor Protocol Number: SHP-GCB-402 | Start Date*: 2016-02-17 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment with Velaglucerase alfa on Bone-related Pathology in Treatment-naïve Patients with Type 1 Gaucher Disease | |||||||||||||
Medical condition: Gaucher Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000378-30 | Sponsor Protocol Number: SMR-3372 | Start Date*: 2020-03-04 | |||||||||||
Sponsor Name:AlgiPharma AS | |||||||||||||
Full Title: A randomised, double-blind, dose finding study of inhaled alginate oligosaccharide (OligoG) vs placebo in patients with Cystic Fibrosis (CF). | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) IE (Completed) AT (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003678-42 | Sponsor Protocol Number: IIV-316 | Start Date*: 2017-09-01 |
Sponsor Name:RIVM [...] | ||
Full Title: Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands... | ||
Medical condition: Pertussis infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) FI (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005879-16 | Sponsor Protocol Number: GRC17536-201 | Start Date*: 2012-06-11 | |||||||||||
Sponsor Name:Glenmark Pharmaceuticals SA | |||||||||||||
Full Title: A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic N... | |||||||||||||
Medical condition: Pain associated with diabetic peripheral neuropathy (DPN). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
